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Abstract
The investigation of new adjuvants is essential for the development of efficacious
vaccines. Chitosan (CS), a derivative of chitin, has been shown to act as an adjuvant,
improving vaccine‐induced immune responses. However, the effect of CS molecular
weight (MW) on this adjuvanticity has not been investigated, despite MW having been
shown to impact CS biological properties. Here, two MW variants of CS were investigated for their ability to enhance vaccine‐elicited immune responses in vitro and in
vivo, using a single‐dose influenza A virus (IAV) protein vaccine model. Both low‐
molecular‐weight (LMW) and high‐molecular‐weight (HMW) CS‐induced interferon
regulatory factor pathway signaling, antigen‐presenting cell activation, and cytokine
messenger RNA (mRNA) production, with LMW inducing higher mRNA levels at 24 h
and HMW elevating mRNA responses at 48 h. LMW and HMW CS also induced
adaptive immune responses after vaccination, indicated by enhanced immunoglobulin
G production in mice receiving LMW CS and increased CD4 interleukin 4 (IL‐4) and IL‐2
production in mice receiving HMW CS. Importantly, both LMW and HMW CS
adjuvantation reduced morbidity following homologous IAV challenge. Taken together,
these results support that LMW and HMW CS can act as adjuvants, although this
protection may be mediated through distinct mechanisms based on CS MW.
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| INTRODUCTION

the development of effective memory responses and protection
against infection (Coffman et al., 2010; Di Pasquale et al., 2015;

Adjuvants have been used for over 85 years to improve the im-

McKee et al., 2010). In protein vaccines, adjuvants are particularly

munogenicity of vaccines (Coffman et al., 2010; Di Pasquale et al.,

important, as protein vaccines lack natural pathogen‐associated

2015; McKee et al., 2010). Adjuvants are used to enhance innate and

molecular patterns that initiate innate immune responses through

adaptive immune responses induced during vaccination, allowing for

activation of pattern recognition receptors (Bergmann‐Leitner &

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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Leitner, 2014; Di Pasquale et al., 2015; Modlin, 2012). Innate im-

studies do not define the properties of the CS used, making it diffi-

mune responses are required to activate adaptive T‐cell responses,

cult to draw conclusions about the effect of MW on adjuvanticity of

which enhance cellular and humoral immunity. Currently, there ex-

CS (Chang et al., 2010; Ghendon et al., 2008; Sui, Chen, Fang, et al.,

ists only a small number of adjuvants that are used in vaccines that

2010; Sui, Chen, Wu, et al., 2010; Wang et al., 2012; Xie et al., 2007).

are approved for human use in the US. Adjuvants used in approved

Given that CS MW has been shown to impact its interactions with

human vaccines include aluminum salts (alum), oil‐in‐water emulsions

proteins and phospholipid bilayers (Bekale et al., 2015; Fang et al.,

(such as MF‐59), monophosphoryl lipid A (MPLA), saponins (QS‐21),

2001), MW has the potential to alter how CS interacts with host

and unmethylated CpG oligodeoxynucleotides (Centers for Disease

cells, which could affect CS adjuvanticity during vaccination.

Control and Prevention, 2016). Each adjuvant induces unique im-

In this report, the effect of MW on the adjuvant properties of CS

mune responses, allowing for tailoring of the vaccine‐induced re-

was investigated. Given that many previous investigations of CS have

sponse to the target pathogen (Awate et al., 2013; Ciabattini et al.,

used MW ranging from 50 to 1000 kDa, a low‐molecular‐weight

2016; Coffman et al., 2010; Di Pasquale et al., 2015; Ho et al., 2018;

(LMW) CS variant examining the lower range and a high‐molecular‐

Kwissa et al., 2012; Lee & Nguyen, 2015; McKee et al., 2010, 2007;

weight (HMW) CS variant examining the middle range were selected

McKee & Marrack, 2017). However, the small number of adjuvants

for this investigation. In addition, an influenza A virus (IAV) model

used in approved human vaccines limits the ability to finetune the

was used to determine CS adjuvanticity, given the need for im-

vaccine‐induced immune response. Continued investigation of new

provements to the IAV vaccine strategy. IAV is an RNA virus and

materials that can act as vaccine adjuvants will increase the pool of

during replication, point mutations can be incorporated in the outer

available adjuvants that can be utilized during the generation of

coat proteins in a process known as antigenic drift. Antigenic drift

vaccines.

variants escape antibody‐mediated neutralization; thus, vaccines

Chitosan (CS), an immunostimulatory biomaterial, has been in-

have to be reformulated each year according to the seasonal IAV

vestigated as a possible adjuvant (Carroll et al., 2016; Chang et al.,

strains currently circulating in the population. For example, early

2010; Ghendon et al., 2008, 2009; Heffernan et al., 2011; Scherließ

data from the 2019–2020 influenza season estimate the vaccine was

et al., 2013; Sui, Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010;

only 45% effective in preventing laboratory‐confirmed influenza

Wang et al., 2012; Westerink et al., 2002; Xie et al., 2007). CS is a

(Dawood et al., 2020). One method to improve IAV vaccine efficacy

positively charged, linear polysaccharide, which is a partially deace-

is to incorporate adjuvants, which are thought to boost the im-

tylated derivative of the natural compound chitin derived from crus-

munogenicity of IAV proteins in an attempt to induce broader, more

taceans (Ravi Kumar, 2000). CS is biodegradable, biocompatible, and

universal protection against seasonal strains that undergo antigenic

nontoxic and has been investigated for many applications, including

drift (Tregoning et al., 2018). Here, we investigate the ability of

tissue engineering and delivery of genes, drugs, and DNA vaccines

LMW CS, averaging 50–190 kDa, and HMW CS, averaging

(Farris et al., 2017; Mohebbi et al., 2019; Ravi Kumar, 2000). Despite

310–375 kDa, to act as adjuvants in an IAV protein vaccine by en-

being considered nonimmunogenic (Dragostin et al., 2016; Mohebbi

hancing antigen‐presenting cell (APC) function, increasing antibody

et al., 2019; Ravi Kumar, 2000), CS and CS particles have been show

production, and providing protection against influenza challenge.

to act as immunostimulants in vitro and in vivo (Bueter et al., 2011;
Carroll et al., 2016; Chang et al., 2010; Ghendon et al., 2008, 2009;
Heffernan et al., 2011; Lin et al., 2014; Mori et al., 2012; Scherließ

2 |
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et al., 2013; Sui, Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010;
Wang et al., 2012; Westerink et al., 2002; Xie et al., 2007).

2.1 | Ethics statement

As an adjuvant, CS has been shown to improve protection
against lethal infection, antibody responses, and interferon (IFN)‐γ

Experimental procedures using mice were conducted in accordance

production by T cells in mouse models using a variety of vaccination

with the US Animal Welfare Act and approved by the Institutional

routes and antigens (Carroll et al., 2016; Chang et al., 2010; Ghendon

Animal Care and Use Committee at the University of Nebraska‐

et al., 2008, 2009; Heffernan et al., 2011; Scherließ et al., 2013; Sui,

Lincoln. IAVs are Biosafety Level (BSL)‐2 pathogens and were used in

Chen, Fang, et al., 2010; Sui, Chen, Wu, et al., 2010; Wang et al.,

accordance with guidelines set forth in Biosafety in Microbiological

2012; Westerink et al., 2002; Xie et al., 2007). However CS is a

and Biomedical Laboratories, Centers for Disease Control, and

polymer, and, thus, its properties are heavily influenced by para-

National Institutes of Health. All personnel was trained in BSL‐2

meters including molecular weight (MW) (Aggarwal & Matthew,

safety and protocols were approved by the University of Nebraska‐

2009; Huang et al., 2005, 2004; Kiang et al., 2004; Maurstad et al.,

Lincoln Institutional Biosafety Committee (Protocol #112).

2007; Ravi Kumar, 2000; Shukla et al., 2013). Previous studies examining the adjuvanticity of CS have investigated single and very
broad MW ranges of CS (150–400 kDa [Carroll et al., 2016],

2.2 | Mice

50–1000 kDa [Scherließ et al., 2013], 200–600 kDa [Heffernan et al.,
2011], 190–310 kDa [Westerink et al., 2002], and the mixture of

Female BALB/cByJ mice were purchased from Jackson Laboratories

300 and 10 kDa [Yuri Ghendon et al., 2009]), but many published

(Bar Harbor). Male OT‐II T‐cell receptor transgenic mice (B6.Cg‐Tg

LAMPE
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(TcraTcrb)425Cbn/J) on the C57BL/6 background were also used in

3

at −80°C. From the TRIzol reagent, RNA was isolated using either

select experiments. Breeding pairs for the OT‐II mice were pur-

a RiboPure kit (Ambion™ #AM1924) or without a kit as described

chased from Jackson Laboratories. OT‐II mice were used for the

briefly here. After thawing, 200 µl chloroform was added to cells in

generation of bone marrow‐derived dendritic cells (BMDCs) that

TRIzol. Samples were then vortexed and centrifuged at 9200g for

were used for flow cytometric analysis of cellular activation and

15 min at 4°C. The aqueous layer was collected after centrifuga-

viability. Three‐ to six‐month‐old mice were used in all experiments.

tion and the RNA was precipitated with isopropanol for 15 min at
room temperature. The RNA pellet was washed with 75% ethanol,
samples were centrifuged, and the supernatant was discarded.

2.3

| BMDC culture and CS treatment

Samples were air‐dried at 37°C and resuspended in 50 µl RNase‐
free double‐distilled water (ddH2O). Complementary DNA (cDNA)

BMDCs were generated as previously described (Lampe et al., 2020).

was obtained using Applied Biosystems High‐Capacity cDNA Re-

Bone marrow was collected by washing the femurs and tibias of mice

verse Transcription Kit (Thermo Fisher Scientific). Following

with phosphate‐buffered saline (PBS) using a 3 ml syringe with a 26 G

cDNA generation, quantitative reverse transcription‐polymerase

needle. Red blood cells in the cellular suspension were lysed using

chain reaction (qRT‐PCR; Step One Plus; Applied Biosystems

ammonium–chloride–potassium (ACK) buffer, remaining cells were

Fisher Scientific) was used for amplification and quantification of

collected, washed, and resuspended at 2 × 106 cells/ml. After re-

select genes. Primers were purchased from Applied Biosystems,

suspension, 1 ml of cells were cultured in six‐well plates in a total

Il6 (Mm00446190_m1), Cxcl10 (Mm00445235_m1), and Ifnb1

volume of 5 ml of complete Roswell Park Memorial Institute (RPMI)

(Mm00439552_s1).

media for 7 days in the presence 5 ng/ml granulocyte‐macrophage
colony‐stimulating factor (GM‐CSF). BMDCs were cultured in RPMI
1640 media (Thermo Fisher Scientific) containing 2‐mM L‐glutamine
(Invitrogen), 100 IU penicillin (Invitrogen), 100 µg/ml streptomycin

2.5 | Flow cytometry of BMDC activation and
viability

(Invitrogen), 10 mM HEPES (Sigma‐Aldrich), 50 µM 2‐mercaptoethanol
(Sigma‐Aldrich), and 7% fetal bovine serum (FBS) (Hyclone). On Days 3

To assess BMDC activation status and viability after CS treatment,

and 5 after initiation of culture, half of the media was removed and

BMDCs were treated for 24 h. After treatment, cells were harvested

replaced with fresh media containing 5 ng/ml GM‐CSF (Lampe

and stained for CD11b BV421 (BioLegend, clone: M1/70), CD11c

et al., 2020).

APC Fire 750 (BioLegend, clone: N418), I‐A/I‐E major histocompat-

On Day 7 after initiation of culture, BMDCs were collected from

ibility complex (MHC) Class II V500 (BD Biosciences, clone: M5/

six‐well plates by gentle washing, counted, and replated in 12‐well

114.15.2), CD40 PE‐Cy7 (BioLegend, clone: 3/23), CD80 PE (BD

6

plates at 2 × 10 cells in 1 ml total complete RPMI media containing

Pharmingen, clone: 16‐10‐A1), CD86 APC (eBiosciences, clone: GL1),

5 ng/ml GM‐CSF for treatment. LMW and HMW CS were separately

Annexin V PE (BD Biosciences), and 7‐aminoactinomycin D (7AAD;

added to the media at the indicated concentrations on day seven and

BD Biosciences). Samples were analyzed on a Cytek DxP10 (Cytek

cells were incubated at 37°C for the indicated time. A range of CS

Biosciences, Inc.) flow at the University of Nebraska‐Lincoln Flow

doses spanning 0.01–10 µg/ml was chosen to determine the doses at

Cytometry Service Center. Data were analyzed using FlowJo soft-

which of CS‐induced detectable responses. Both LMW and HMW CS

ware (Becton, Dickinson and Company).

were obtained from Sigma‐Aldrich. Both LMW and HMW CS were
suspended at 5 mg/ml in 1% acetic acid solution before dilution to
the indicated treatment dose in cell media. Nonparticle forms of CS
were used throughout the report. As indicated by the supplier, LMW

2.6 | Assessment of nuclear factor‐κB and
interferon regulatory factor pathway activation

CS averaged 50–190 kDa with 75%–85% deacetylation. HMW CS
averaged 310–375 kDa with greater than 75% deacetylation (-

J774‐Dual™ Cells (Invivogen) were grown in high‐glucose

Table S1). LMW and HMW CS were tested for endotoxin impurities

Dulbecco's modified Eagle's medium (Thermo Fisher Scientific),

using a LAL Endochrome‐K Kit (Charles River) and found to be

1.5 g/L sodium bicarbonate (Thermo Fisher Scientific), 1.0 mM

endotoxin‐free (Table S1). Cells were also treated with 0.01 µg/ml

sodium pyruvate (Thermo Fisher Scientific), 10% FBS (Thermo

MPLA a known agonist of TLR4 (Invivogen) as a positive control.

Fisher Scientific), 100 µg/ml Normocin™ (Invivogen), 100 U/ml
penicillin (Thermo Fisher Scientific), and 100 µg/ml streptomycin
(Thermo Fisher Scientific). J774‐Dual™ Cells were treated with

2.4 | Extraction of RNA and real‐time quantitative
reverse transcription‐polymerase chain reaction
analysis

LMW or HMW CS at the indicated concentrations and for the
indicated duration. Cells were also treated with 0.01 µg/ml MPLA
(Invivogen) as a positive control. After treatment, secreted alkaline phosphatase (SEAP) and Lucia luciferase expression were

After designated CS treatment duration, BMDCs were harvested

measured using a protocol provided by Invivogen. SEAP expres-

and resuspended in 500 µl TRIzol reagent (Ambion) and placed

sion was measured using an Epoch Microplate Spectrophotometer

4
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2.9 | Influenza virus challenge

Veritas™ Microplate Luminometer (Turner BioSystems). Results
were normalized to total protein, measured via bicinchoninic acid

Mice were anesthetized with an isoflurane vaporizer and challenged

assay using an Epoch Microplate Spectrophotometer (Agilent

with a homologous IAV, pdm09 (H1N1) or PR8 (H1N1), based on

Technologies).

immunizing antigen. Pdm09 was diluted in PBS in 30 µl total and
administered i.n. at 6.3 × 105 chicken embryo infectious dose
(CEID)50. PR8 was diluted in sterile PBS in 30 µl and administered i.n.

2.7

| Immunizations

at 5000 EID50. After a viral challenge, mouse weight and survival
were monitored daily for up to 30 days. IAV, A/California/07/2009

All immunizations were performed under anesthesia using an

(H1N1) pdm09, FR‐201, was obtained through the Influenza Reagent

isoflurane

administered

Resource, Influenza Division, WHO Collaborating Center for Sur-

intramuscularly (i.m.) in 50 µl total volume. All immunizations

veillance, Epidemiology and Control of Influenza, Centers for Disease

contained either 5 µg EndoFit ovalbumin (OVA) protein (Invivogen)

Control and Prevention.

vaporizer.

Immunizations

were

or 1 µg hemagglutinin (HA) recombinant protein from A/California/
07/2009 H1N1 (pdm09) (International Reagent Resource), or 1 µg
HA protein from A/Puerto Rico/8/34 (Sino Biological Inc.), as in-

2.10 |

T‐cells examination by flow cytometry

dicated. In addition to antigen, mice received LMW or HMW CS at
4 or 40 µg. Low dose, 1 µg antigen per mouse vaccinations was

Mice were administered an IAV challenge (PR8) as described above

chosen to allow for modest CS MW effects to be observed, as well

4.5 weeks after immunization. Two and 5 days after the challenge,

as to investigate potential antigen dose sparing effects of CS ad-

mice were killed and draining lymph node (DLN, a pool of cervical

juvantation (Lampe et al., 2020). As a negative control, mice were

and mediastinal lymph node [LN]) and lungs were examined. DLN

immunized with antigen protein alone. Low dose PR8 immuniza-

samples were prepared as single cell suspensions by dissociation

tions were delivered intranasally (i.n.) at 500 egg infective dose

through a 70 µm screen. Lungs were perfused before removal,

(EID)50 in 30 µl PBS as a positive control for protection against viral

chopped into a slurry, and incubated with collagenase‐D (Sigma‐

challenge and antibody production. Antigen combined with 20 µg

Aldrich; 5 µg/ml final concentration) and DNAse (Invitrogen;

MPLA delivered i.m. was also used as a positive control for anti-

100 U/ml final concentration) for 1 h at 37°C before being filtered

body production (Lampe et al., 2020). Mice were weighed for up to

through a 70 µm screen. Lung samples were then treated with ACK

7 days after immunization to assess adverse effects caused by

buffer. Single cell suspensions were counted, and viability analyzed

adjuvantation.

using a TC10™ Automated Cell Counter (Bio‐Rad Hercules). For intracellular cytokine staining (interleukin [IL]‐2, IFN‐γ, and IL‐4), single
cell suspensions were restimulated with PR8 HA peptides alone

2.8

| Antibody production after immunization

(DLN) or PR8 HA peptide pulsed LB27.4 cells (ATCC) (lung). IAV
peptides used for restimulation included HA peptide 126–138

Three and four weeks after immunization, blood was collected

(HNTNGVTAACSHE), HA peptide 518–526 (IYSTVAASL), and HA

from mice and serum separated by centrifugation at 4°C for

peptide 126–140 (SSFERFEIFPKESSW). Cells were restimulated with

15 min at 16,300g. Serum was used to perform an enzyme‐linked

peptide for a total of 6 h with 10 µg/ml Brefeldin A (Sigma‐Aldrich)

immunosorbent assay (ELISA) to assess antibody titers. ELISAs

addition for the final 2 h. Single cell suspensions were stained for:

were performed using a Clear Flat‐Bottom Immuno 96‐well plate

CD3 FITC (BioLegend, clone: 145‐2C11), CD4 BV421 (BioLegend,

(Thermo Fisher Scientific) that had been coated overnight at 4°C

clone: GK1.5), CD8 APC/Fire 750 (BioLegend, clone: 53‐6.7), CD44

with the immunizing antigen at 10 µg/ml diluted in PBS. After

PE‐Cy7 (eBiosciences, clone: IM7), CD69 PE‐Cy7 (eBiosciences,

coating, plates were washed with PBS and blocked for 1 h with

clone:H1.2F3), CD103 PerCP‐Cy5.5 (BioLegend, clone: 2E7), IL‐2

PBS containing 2% FBS and 10 mM HEPES (Sigma‐Aldrich)

FITC (eBiosciences, clone:JES6‐5H4), IFN‐γ APC (eBiosciences,

(blocking buffer). Serum was diluted to1:20 in blocking buffer

clone: XMG1.2), and IL‐4 PE (BioLegend, clone: 11B11). Samples

and serially diluted twofold. Plates were then incubated at room

were analyzed on a Cytek DxP10 (Cytek Biosciences, Inc.) at the

temperature for 2–3 h before alkaline phosphatase‐conjugated

University of Nebraska‐Lincoln Flow Cytometry Service Center. Data

secondary antibodies against immunoglobulin G (IgG), IgG2a, or

were analyzed using FlowJo software (FlowJo, LLC, a subsidiary of

IgG1 (Southern Biotech) were added for 1 h at room temperature.

Becton, Dickinson and Company).

After incubation with secondary antibodies, plates were developed in the dark using p‐nitrophenyl phosphate for 30 min. Plates
were then read at an optical density (OD) of 405 nm on a BioTek

2.11 |

Statistical analysis

ELx808 (BioTek). OD was used to calculate endpoint titers by
determining the reciprocal of the dilution at which the sample OD

All in vitro results are indicative of 2–17 replicates done within 1–3

fell below two times the background.

individual experiments, as indicated in the figure legend. All in vivo

LAMPE
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results are indicative of an experiment with an n of 5. Statistical

and 48 h after treatment, BMDCs were harvested and RNA isolated for

analyses were completed using one‐way analysis of variance with

gene expression analysis by qRT‐PCR. Gene expression was normalized

Sidak's multiple comparisons test or Tukey's multiple comparisons

to untreated cells (media alone), which is set to 1 and indicated by the

test post hoc analysis, as indicated in the figure legend. Statistical

dotted line of respective graphs. Cells treated with 0.01 µg/ml MPLA

analyses performed using Prism software (GraphPad Prism 5).

served as a positive control for cytokine gene expression.
At 24 h after treatment, both LMW and HMW CS at 1 µg/
ml‐induced elevated Il6 mRNA levels compared to untreated cells

3

| RESULTS

and cells treated with MPLA (Figure 1a). Treatment with CS at 0.01,
0.1, or 10 µg/ml‐induced mRNA levels that were not significantly

3.1 | LMW and HMW CS induce cytokine
production by BMDCs in vitro

different from untreated cells, but these levels were significantly
lower than cells treated with MPLA (Figure 1a). No significant differences in Il6 mRNA levels were observed between BMDCs treated

To assess the immune‐modulatory effects of CS on APCs in vitro,

with the same doses of LMW and HMW CS (Figure 1a). In contrast to

BMDCs were treated with LMW (50–190 kDa) or HMW (310–375 kDa)

Il6 mRNA levels, 10 µg/ml treatment induced significantly higher

CS at doses ranging from 0.01 to 10 µg/ml for 24 or 48 h before as-

levels of Ifnb1 and Cxcl10 mRNA for both LMW and HMW CS

sessment of Il6, Ifnb1, and Cxcl10 messenger RNA (mRNA) levels.

compared to all lower treatment doses and MPLA treatment

Examination of cytokine and chemokine mRNA expression was used as

(Figure 1b,c). No significant increases in Ifnb1 or Cxcl10 mRNA levels

an initial indicator of dendritic cell activation, with elevated mRNA ex-

over untreated cells were observed with either LMW or HMW CS

pression indicating enhanced APC potential (Lampe et al., 2020). At 24

treatment at 0.01, 0.1, or 1 µg/ml, while 10 µg/ml of both LMW and

(a)

(b)

(c)

(d)

(e)

(f)

F I G U R E 1 LMW and HMW CS significantly enhances cytokine production by BMDCs 24 h after treatment. BMDCs (n = 3) were treated
with varying doses of two varieties of CS or 0.01 µg/ml MPLA as a positive control. BMDCs were treated for 24 (a–c) or 48 h (d–f) before cells
were harvested, placed in TRIzol reagent, and RNA was isolated. qRT‐PCR was performed on complementary DNA generated from the isolated
RNA. qRT‐PCR was performed for Il6 (a, d), Ifnb1 (b, e), and Cxcl10 (c, f). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with
Sidak's multiple comparisons test compared to untreated BMDCs or indicated comparison. The dotted line indicates untreated BMDC (media
alone) reference control set to 1. Error bars represent SEM. ANOVA, analysis of variance; BMDC, bone marrow‐derived dendritic cell; CS,
chitosan; HMW, high molecular weight; LMW, low molecular weight; MPLA, monophosphoryl lipid A; mRNA, messenger RNA;
qRT‐PCR, quantitative reverse transcription‐polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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HMW CS significantly elevated Ifnb1 and Cxcl10 mRNA levels over

expression compared to untreated controls after 24 h (Figure 2a),

MPLA‐treated cells (Figure 1b,c). When comparing LMW CS treat-

which may indicate that 1 µg/ml MPLA at this time point is not an

ment to HMW CS treatment, significantly higher Ifnb1 and Cxcl10

optimal treatment condition to observe optimal MPLA effects on

mRNA levels were observed after treatment with 10 µg/ml LMW CS

CD80 expression in BMDCs. BMDCs treated with LMW CS at any

compared to treatment with 10 µg/ml HMW CS.

dose did not display increased CD80 expression compared to un-

In contrast to the 24 h results, no significant changes in Il6

treated BMDCs, with high‐dose (10 µg/ml) LMW resulting in de-

mRNA were observed after 48 h in LMW or HMW treated cells

creased

compared to the untreated control, and all CS treated cells displayed

(Figure 2a). When BMDCs were treated with HMW CS at 0.1 and

CD80

expression

compared

to

untreated

BMDCs

significantly lower Il6 mRNA levels compared to MPLA‐treated cells

1 µg/ml significantly increased CD80 expression was observed

(Figure 1d). In addition, the increases in Ifnb1 and Cxcl10 mRNA

compared to untreated BMDCs (Figure 2a). No significant differ-

levels that were induced by LMW CS treatment at 24 h were not

ences were observed between untreated BMDCs and those treated

sustained through 48 h, with no significant changes observed in Ifnb1

with 0.01 and 10 µg/ml HMW CS (Figure 2a). Cells treated with 0.1‐

or Cxcl10 mRNA levels after LMW CS treatment at any dose com-

µg/ml HMW CS displayed the highest expression of CD80 compared

pared to untreated or MPLA‐treated BMDCs (Figure 1e,f). However,

to other HMW CS doses (Figure 2a). HMW CS treatment at 10 µg/ml

HMW CS treatment at 10 µg/ml did significantly increase Ifnb1 and

resulted in significantly higher CD80 expression compared to cells

Cxcl10 mRNA levels over untreated and MPLA‐treated cells at 48 h

treated with LMW at the same dose (Figure 2a). LMW CS treatment

(Figure 1e,f). Treatment with 10 µg/ml HMW significantly increased

resulted in no significant increases from untreated cells, with LMW

Ifnb1 and Cxcl10 mRNA levels over BMDCs treated with the same

CS treatment at 1 and 10 µg/ml inducing significantly lower CD86

dose of LMW CS at 48 h (Figure 1e,f). Taken together, these results

MFIs compared to untreated cells (Figure 2b). When BMDCs were

suggest that both LMW and HMW CS treatments induce cytokine

treated with HMW CS at 0.01, 1, or 10 µg/ml, no significant increases

and chemokine mRNA expression in BMDCs. LMW and HMW CS

were observed in CD86 MFI compared to untreated BMDCs, while

treatment resulted in similar Il6 mRNA levels at 24 and 48 h. In

HMW CS treatment at 0.1 µg/ml induced significantly higher CD86

contrast, after 24 h treatment, LMW CS treatment induced sig-

MFI compared to untreated cells (Figure 2b). HMW CS treatment at

nificantly higher levels of Ifnb1 and Cxcl10 mRNA compared to HMW

both 0.1 and 1 µg/ml resulted in significantly higher CD86 levels over

CS treatment. However, after 48 h treatment, HMW CS resulted in

treatment with LMW CS at the same doses (Figure 2b). Examination

significantly higher Ifnb1 and Cxcl10 mRNA levels over LMW CS,

of CD40 expression revealed no significant differences between

suggesting a difference in the kinetics of cytokine mRNA induction

untreated cells and those treated with LMW or HMW CS at any dose

after LMW and HMW CS treatment.

(Figure 2c). As expected, MPLA treatment resulted in significantly
higher CD40 MFI levels compared to untreated cells and all treatment groups receiving LMW or HMW CS at any dose (Figure 2c).

3.2

| HMW CS activates BMDCs in vitro

MPLA‐treated BMDCs expressed significantly elevated MHC
class II expression over cells treated with LMW CS at 1 and 10 µg/ml

After observing increased cytokine and chemokine mRNA levels in

and HMW CS at 10 µg/ml, while HMW CS treatment at 0.1 µg/ml

BMDCs that had been treated with LMW or HMW CS relative to

induced significantly higher MHC class II expression compared to

untreated cells, BMDC activation status after CS treatment was in-

MPLA treatment (Figure 2d). MHC class II examination showed that

vestigated. BMDC activation and maturation, including upregulation

treatment with LMW CS at any dose did not induce increases in

of costimulatory and MHC class II molecule expression, is essential

expression over untreated cells (Figure 2d). LMW CS treatment of

for effective activation of naïve T cells (Lanzavecchia & Sallusto,

10 µg/ml induced the lowest MHC class II expression levels com-

2001). MHC class II is required for the presentation of antigen to

pared to all other LMW CS treatment doses (Figure 2d). MHC class II

CD4 T cells, while CD80, CD86, and CD40 serve as costimulatory

MFIs in BMDCs treated with HMW CS at 0.01, 1, and 10 µg/ml were

molecules that provide secondary signals during T‐cell activation,

not significantly changed from untreated cells; however, 0.1 µg/ml

which impacts T‐cell function (Hubo et al., 2013). To assess BMDC

HMW CS treatment resulted in significantly elevated MHC class II

activation after CS treatment, BMDCs were treated with varying

levels compared to untreated cells and cells treated with other doses

concentrations of LMW or HMW CS for 24 h. Again, cells treated

of HMW CS (Figure 2d). In addition, HMW CS treatment at 0.1 and

with MPLA served as a positive control (Goff et al., 2015; Mesa et al.,

10 µg/ml resulted in elevated MHC class II MFIs compared to LMW

2004). After treatment, cells were analyzed using flow cytometry for

CS treatment at the same doses (Figure 2d). In addition to inducing

the expression level of surface markers: CD80, CD86, CD40, and

cytokine and chemokine mRNA production (Figure 1) and increasing

MHC class II (Figure 2). Mean fluorescence intensity (MFI), a mea-

activation markers on BMDCs (Figure 2), LMW and HMW CS

sure of staining intensity, was used to compare the relative expres-

treatment at 10 µg/ml significantly increased BMDC Annexin V

sion levels of these surface markers between treatment groups.

staining over untreated cells, but no CS treatment increased 7AAD

All treatment groups, besides LMW CS at 10 µg/ml, resulted in

or Annexin V+/7AAD+ double‐positive staining compared to un-

significantly elevated CD80 expression compared to MPLA‐treated

treated cells (Figure S1), suggesting LMW and HMW CS treatment

BMDCs (Figure 2a). MPLA treatment did not result in elevated CD80

may induce low levels of apoptosis.
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F I G U R E 2 HMW CS treatment significantly increases the activation status of BMDCs. BMDCs (n = 3) were treated with varying doses of
two varieties of CS for 24 h or with MPLA at 1 µg as a positive control for activation. Untreated cells (media alone) were used as negative
control. After treatment, BMDCs were harvested and CD11b+/CD11c+ cells were analyzed for CD80 (a), CD86 (b), CD40 (c), and I‐A/I‐E major
histocompatibility complex (MHC) class II (d) using flow cytometry. Cells were examined for the level of expression using mean fluorescent
intensity (MFI). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Sidak's multiple
comparisons test. Error bars represent SEM. ANOVA, analysis of variance; BMDC, bone marrow‐derived dendritic cell; CS, chitosan; HMW, high
molecular weight; LMW, low molecular weight; MPLA, monophosphoryl lipid A [Color figure can be viewed at wileyonlinelibrary.com]

Analysis of costimulatory molecules and MHC class II as indicators of BMDC activation revealed that LMW and HMW CS result

7AAD or Annexin V+/7AAD+ double‐positive staining compared to
untreated cells.

in different activation marker profiles. HMW CS‐induced higher expression of CD80, CD86, and MHC class II than LMW CS treatment
at corresponding doses. Neither LMW nor HMW CS treatment induced upregulation of the costimulatory molecule CD40 compared

3.3 | CS induces interferon regulatory factor, but
not nuclear factor‐κB, pathway signaling

to untreated cells. Furthermore, the BMDC activation profiles observed after LMW and HMW CS treatment, indicated by cytokine/

To examine how CS treatment may induce signaling through cano-

chemokine expression and surface markers, do not appear to be

nical innate immune response transcription factor pathways, CS was

induced by high levels of CS‐associated cell death, as evidenced by

used to treat J774‐Dual™ Cells, a mouse macrophage‐like cell line

8
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engineered to report changes in interferon regulatory factor (IRF)

8 or 12 h with either LMW or HMW CS treatment (Figure 3). Sig-

and nuclear factor (NF)‐κB pathway activation via Lucia luciferase

nificant IRF pathway activation was observed after 18 h in 50 µg/ml

and SEAP reporters, respectively (Lampe et al., 2020). J774‐Dual™

HMW CS treated cells compared to untreated cells (Figure 3). At 24 h,

Cells were treated with varying doses of LMW and HMW CS for 8,

HMW CS at 10 µg/ml‐induced significant IRF pathway activation

12, 18, 24, 36, and 48 h. IRF activation was normalized to untreated

compared to untreated cells (Figure 3). By 36 h, both LMW and HMW

cells, which is set to 1 and indicated by the dashed line. MPLA at

CS at 50‐µg/ml‐induced significant IRF pathway activation over un-

0.1 µg/ml treatment was used as a positive control for IRF pathway

treated cells (Figure 3). After 48 h treatment with both LMW and

activation (Mata‐Haro et al., 2007), resulting in significant IRF

HMW CS at 10‐ and 50‐µg/ml‐induced significant IRF pathway

pathway activation over untreated cells at all time points (Figure 3).

activation over untreated cells (Figure 3). MPLA treatment induced

No significant IRF pathway activation compared to untreated cells

greater IRF pathway activation compared to LMW and HMW CS

was observed after treatment with LMW or HMW CS at 0.01, 0.1, 1,

treated cells at all doses for 8, 12, 18, 24, and 36 h treatments

or 5 µg/ml (Figure 3 and data not shown). In addition, no significant

(Figure 3). However, no significant differences in IRF pathway acti-

IRF pathway activation was observed over untreated cells after

vation was observed at 48 h between MPLA‐treated cells and LMW

F I G U R E 3 LMW and HMW CS induce IRF pathway signaling. J774‐Dual™ cells (n = 12–17) were treated with two varieties of CS at the
indicated dose. J774 dual cells use the Lucia luciferase gene to report IRF activity. Treatment durations included 8, 12, 18, 24, 36, and 48 h.
Reporter output normalized to total protein and fold change in relative light units (RLU) calculated over untreated cells (media alone). *p ≤ .05,
**p ≤ .01, ***p ≤ .001, ****p ≤ .0001 compared to MPLA‐treated (red and blue asterisk) and untreated (black asterisk) cells by two‐way ANOVA
with Tukey's multiple comparisons test. Error bars represent SEM. ANOVA, analysis of variance; CS, chitosan; HMW, high molecular weight;
IRF, interferon regulatory factor; LMW, low molecular weight; MPLA, monophosphoryl lipid A [Color figure can be viewed at
wileyonlinelibrary.com]
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CS at 50 µg/ml and HMW CS at both 50 and 10 µg/ml (Figure 3). No

LMW or HMW CS at 40 µg showed increased levels of serum anti‐

significant differences in IRF pathway activation were observed at any

OVA IgG compared to mice receiving OVA protein alone; however,

time point between LMW CS and HMW CS treated cells receiving the

this increase was only significant in the 40 µg LMW CS group, sug-

same dose (Figure 3).

gesting that LMW, but not HMW CS is able to significantly increase

In contrast to the IRF pathway activation, no significant NF‐κB

anti‐OVA IgG antibody titers after vaccination (Figure 4b).

activation over untreated cells was observed with CS treatment at

A separate experiment was conducted to determine if LMW or

any time point investigated (Figure S2). Taken together, examination

HMW CS adjuvantation could allow for antigen dose sparing effects.

of IRF and NF‐κB pathway activation suggests that both LMW and

A low‐dose vaccination of 1 µg HA protein from pdm09 H1N1 was

HMW CS at 10 and 50 µg/ml are able to activate the IRF pathway to

chosen to allow for modest CS MW effects to be observed and to

a similar degree, despite seeing differential effects of LMW and

examine potential antigen dose sparing effects of CS adjuvantation

HMW CS on BMDC cytokine production and surface activation

using a relevant IAV antigen. Mice were vaccinated with a single low

marker expression. However, IRF pathway activation in response to

dose of HA protein alone or combined with LMW or HMW CS at

LMW and HMW CS treatment is delayed compared to MPLA

40 µg. The 40‐µg dose was chosen based on the elevated IgG titers

treatment.

after vaccination with 40‐µg LMW CS. As a positive control, mice
were infected with a low‐dose (500 EID50) PR8 virus at the time of
immunization. Serum was collected 4 weeks after vaccination and

3.4 | LMW CS adjuvantation enhances IgG
production after vaccination

using ELISA (Figure 4c,d).

After observing innate immune activation induced by both LMW and

nificantly higher IgG2a endpoint titers compared to mice receiving

examined for HA‐specific IgG subtype, IgG2a and IgG1, antibodies
Mice previously infected with the PR8 virus displayed sig-

HMW CS treatment in vitro, LMW and HMW CS were investigated

HA alone or HA combined with LMW or HMW CS (Figure 4c). No

for their ability to act as adjuvants during protein vaccination in a

significant differences in IgG2a and IgG1 titers were observed be-

mouse model. The effect of LMW and HMW CS on antibody pro-

tween mice receiving HA protein alone and those receiving LMW or

duction was examined. To do this, mice were first vaccinated i.m.

HMW CS (Figure 4c,d). However, LMW and HMW CS mice displayed

with 5 µg of a model antigen OVA protein in combination with LMW

IgG1 endpoint titers greater than or equal to 100 (Figure 4d). To-

or HMW CS at 4 or 40 µg per mouse. Two doses of CS were ex-

gether, results examining antibody production after LMW and HMW

amined to determine the effective dose that was able to enhance

CS vaccination suggest that LMW CS, but not HMW CS, as an

antibody production. The 40 µg per mouse dose was similar to the

adjuvant is able to significantly increase IgG production after

dose investigated by other groups (Da Silva et al., 2009; Sui, Chen,

immunization over unadjuvanted vaccines.

Fang, et al., 2010; Sui, Chen, Wu, et al., 2010; Wang et al., 2012), and
is 4–40‐fold higher than the optimum in vitro dose for cytokine gene
expression and IRF pathway signaling (Figures 1 and 3). We chose an
order of magnitude higher dose for in vivo experiments based on our
previously published report (Lampe et al., 2020), and the presumed

3.5 | LMW and HMW CS improve protection
against homologous IAV challenge compared to
unadjuvanted vaccines

dilution of CS within the injection site, which can reduce the accessibility of CS to APC in the muscle. We also used a 10‐fold lower

After observing significantly enhanced IgG antibody production in

dose (4 µg per mouse) to remain within the range of our in vitro

mice receiving LMW CS, but not HMW CS, during vaccination

studies and to investigate if either LMW or HMW CS was effective at

compared to mice receiving antigen alone, the ability of both LMW

lower doses. As a positive control, mice were vaccinated with OVA

and HMW CS adjuvantation to improve protection against IAV

antigen combined with 20 µg MPLA per mouse (Ko et al., 2017;

challenge was investigated. Mice were immunized i.m. with 1 µg HA

Lampe et al., 2020). At 3 and 4 weeks after vaccination, serum was

protein from pdm09 virus alone or in combination with LMW or

collected from the immunized mice analyzed for anti‐OVA IgG via

HMW CS. LMW and HMW CS were administered at 40 µg per

ELISA.

mouse. As a positive control for protection against IAV infection, a

At 3 weeks postvaccination, all mice vaccinated with OVA +

group of mice was immunized with a low dose (500 EID50) of PR8

MPLA had significantly elevated anti‐OVA IgG levels compared to

virus. Seven weeks after vaccination, mice were administered a

OVA alone and all treatment groups receiving LMW or HMW CS,

homologous viral challenge of 6.3e5 CEID50 pdm09 virus and

except HMW CS at 40 µg (Figure 4a). Enhanced anti‐OVA IgG titers

weighed daily as an indication of infection‐induced morbidity

were also observed three weeks after vaccination in mice receiving

(Figure 5a).

CS, LMW, or HMW, at 40 µg compared to mice receiving OVA alone,

As expected, mice previously infected with the PR8 virus did not

although these differences were not significant (Figure 4a). Four

lose weight in response to the pdm09 viral challenge, displaying

weeks after vaccination, mice receiving MPLA had significantly ele-

significantly less weight loss compared to mice receiving HA alone on

vated anti‐OVA IgG levels compared to OVA alone and mice re-

Days 3–9 (Figure 5a). Mice vaccinated with HA protein alone ex-

ceiving LMW or HMW CS at both doses (Figure 4b). Mice receiving

perienced severe weight loss that peaked around Day 8 after
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(c)

(d)

ET AL.

F I G U R E 4 Mice vaccinated with LMW CS as an adjuvant produce significantly more anti‐OVA IgG compared to mice receiving unadjuvanted
vaccines. Mice (n = 4–5) were vaccinated i.m. with 5 µg OVA protein (a, b) or 1 µg pdm09 HA (c, d) ± CS as an adjuvant at the indicated dose.
Vaccination with antigen alone served as the negative control. As positive control mice were vaccinated with antigen with MPLA (a, b) or mice
were infected with a low‐dose (500 EID50) PR8 virus (c, d). At 3 (a) and 4 weeks (b–d), serum was collected from the mice and ELISA performed
to assess levels of anti‐OVA (a, b) or anti‐PR8 (c, d) antibodies induced by vaccination. Antigen‐specific IgG (a, b), IgG2a (c), and IgG1 (d)
subtypes were investigated. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Sidak's
multiple comparisons test (a, b). *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 between indicated comparisons by one‐way ANOVA with Tukey's
multiple comparisons test (c, d). ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; ELISA, enzyme‐linked immunosorbent assay;
HA, hemagglutinin; HMW, high molecular weight; IgG, immunoglobulin G; i.m., intramuscularly; LMW, low molecular weight; MPLA,
monophosphoryl lipid A; OVA, ovalbumin [Color figure can be viewed at wileyonlinelibrary.com]

infection, with an average of about 26% loss of initial body weight

displaying less weight loss after viral challenge, mice receiving LMW

(Figure 5a). In contrast, mice that were vaccinated with formulations

or HMW CS as adjuvants did not experience significantly increased

that contained either LMW or HMW CS experienced significantly

survival over mice receiving unadjuvanted vaccines (Figure 5b). Mice

less weight loss compared to mice receiving HA protein alone (LMW

receiving HA protein alone experienced 80% survival, with all other

Day 4, HMW Days 5–7) (Figure 5a). Mice receiving LMW CS lost an

groups experiencing 100% survival (Figure 5b). Decreased weight

average of about 15% of their initial weight by Day 8 after the

loss after homologous challenge suggests that both LMW and HMW

challenge, while mice receiving HMW CS lost an average of about

CS can increase protection against morbidity to a similar degree,

11.5% initial weight. There were no significant differences in weight

despite observing differences in vitro in innate activation and in vivo

loss between groups of mice receiving LMW and HMW CS. Although

in antibody production between LMW and HMW CS.
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(b)

F I G U R E 5 Mice vaccinated with formulations that contain CS as an adjuvant experience significantly less weight loss after homologous
infection compared to mice receiving unadjuvanted vaccines. Mice (n = 5) were vaccinated i.m. with 1 µg H1N1 pdm09 HA ± 40 µg CS as an
adjuvant. Four weeks after vaccination mice were challenged with 6.3e5 CEID50 H1N1 pdm09 virus. Following the viral challenge, weight loss
(a) and survival (b) were recorded daily. Five mice were included in each treatment group. *p ≤ .05 by mixed‐effects analysis using Tukey's
multiple comparisons test compared to HA alone. Error bars represent SEM. CEID, chicken embryo infectious dose; CS, chitosan; EID, egg
infective dose; HA, hemagglutinin; HMW, high molecular weight; i.m., intramuscularly; LMW, low molecular weight [Color figure can be viewed
at wileyonlinelibrary.com]

3.6 | LMW and HMW CS induce distinct CD69+/
CD103+ CD4 and CD8 T‐cell populations in the lung
after homologous challenge

alone, these mice did experience an average of 15% and 11.5% loss of
initial body weight, respectively (Figure 5a). The observed weight loss
suggests that the LMW and HMW CS‐induced protection is not
mediated by IgG facilitated sterilizing immunity, and, therefore, cel-

Although mice receiving LMW and HMW CS during vaccination ex-

lular immune responses may be contributing. Thus, the T‐cell popu-

perienced significantly less weight loss than mice receiving antigen

lations present in the lung 2 and 5 days after viral challenge were

(a)

(b)

F I G U R E 6 HMW CS as an adjuvant increases the frequency of CD4 and CD8 lung TRM 5 days after challenge compared to LMW CS. Mice
(n = 5) were vaccinated i.m. with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. Four weeks after vaccination, mice were challenged with
5000 EID50 PR8 viruses. At 5 days after the challenge, mice were killed, and lung T‐cell populations examined using flow cytometry. CD4 (a) and
CD8 (b) T cells were CD69/CD103 expressing populations. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's
multiple comparisons test. ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight;
i.m., intramuscularly; LMW, low molecular weight; TRM, T resident memory cell [Color figure can be viewed at wileyonlinelibrary.com]
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3.7 | HMW CS induces enhanced IL‐4 by CD4 T
cells in the lung 5 days after homologous challenge

pulations, mice were vaccinated i.m. with 1‐µg HA protein from PR8
with or without LMW or HMW CS at 40 µg. Four weeks after vacci-

After observing distinct CD69+/CD103+ CD4 and CD8 T‐cell re-

nation, mice were challenged i.n. with a lethal dose of PR8 virus (5000

sponses in the lung of LMW and HMW CS vaccinated mice following

EID50). Two and 5 days after the homologous challenge, mice were

homologous infection, an investigation of the cytokines produced by

killed, and lungs harvested for T‐cell population analysis using flow

CD4 and CD8 T cells in the lung 5 days after infection was con-

cytometry. CD4 and CD8 T cells were examined for CD69 and CD103

ducted. Mice were vaccinated with a single i.m. dose of 1‐µg re-

expression to indicate lung T resident memory cells (TRM) populations.

combinant HA protein from PR8 alone, or in combination with LMW

Two days after infection, no significant differences were ob-

or HMW CS at 40 µg. Four weeks after vaccination, mice were

+

served between any vaccination groups in the frequency of CD69 /

challenged with a lethal dose of 5000 EID50 PR8 viruses. Five days

CD103+ CD4 or CD8 T cells (Figure S3). However, at Day 5, mice

after the challenge, mice were killed, and lungs were harvested for

receiving HA alone and mice receiving HA with HMW CS displayed

the examination of IFN‐γ and IL‐4 production by CD4 and CD8

+

+

significantly higher CD69 /CD103

CD4 T‐cell frequencies com-

T cells.

pared to mice receiving HA combined with LMW CS (Figure 6a). No

No significant differences in IFN‐γ production by CD4 or CD8

significant differences were observed between mice receiving HA

T cells were observed between LMW or HMW CS vaccinated mice

alone and HA plus HMW CS (Figure 6a). Similarly, to the CD69+/

and mice receiving HA protein alone (Figure S4). In contrast to IFN‐γ,

+

CD103 CD4 T‐cell populations, 5 days after vaccination, mice re-

mice that had received immunizations containing HMW CS displayed

ceiving HA alone or HA with HMW CS displayed significantly higher

significantly elevated frequencies of IL‐4 producing CD4 T cells

CD69+/CD103+ CD8 T‐cell populations compared to mice receiving

compared to mice receiving HA protein alone (Figure 7a). No sig-

HA plus LMW CS (Figure 6b). Examination of CD4 and CD8 TRM

nificant differences in CD4 IL‐4 production were observed between

populations in the lung indicates HMW CS adjuvantation induces

mice receiving LMW CS and those receiving HA alone or HA plus

+

+

CD69 /CD103 CD4 and CD8 T‐cell responses that do not sig-

HMW CS (Figure 7a). No differences were observed between mice

nificantly differ from HA alone, while LMW CS induces significantly

receiving LMW or HMW CS and those receiving HA alone in the

lower CD69+/CD103+ CD4 and CD8 T‐cell populations compared to

frequency of IL‐4+ CD8 T cells (Figure 7b). Investigation of T‐cell

HA alone and HMW CS. The CD69+/CD103+ CD4 and CD8 T‐cell

cytokine production in the lung following homologous challenge

responses observed following homologous challenge suggest that

suggests that HMW CS, but not LMW CS, increases CD4 IL‐4 pro-

HMW CS‐induced significantly elevated CD69+/CD103+ CD4 and

duction in the lung 5 days after homologous viral challenge. There-

CD8 T‐cell populations compared to LMW CS.

fore, elevated IL‐4 production by CD4 T cells in the lungs of mice

(a)

(b)

F I G U R E 7 HMW CS as an adjuvant increases IL‐4 production by CD4 T cells in the lung 5 days after challenge. Mice (n = 5) were vaccinated
i.m. with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. Four weeks after vaccination mice were challenged with 5000 EID50 H1N1 PR8 virus.
Five days after the challenge, mice were killed, and lung T‐cell cytokine production was examined using flow cytometry. CD4 (a) and CD8
(b) T cells were examined for IL‐4 production. *p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's multiple
comparisons test. ANOVA, analysis of variance; CS, chitosan; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight; IL‐4,
interleukin 4; i.m., intramuscularly; LMW, low molecular weight [Color figure can be viewed at wileyonlinelibrary.com]
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vaccinated with HMW CS may be contributing to the enhanced

morbidity observed in LMW and HMW CS vaccinated mice com-

protection observed with HMW CS adjuvantation. However, IL‐4 is

pared to those receiving antigen alone. Mice were vaccinated as

not elevated with LMW CS adjuvantation, suggesting that LMW and

above, i.m. with 1 µg HA protein from PR8 with or without LMW or

HMW CS may be inducing enhanced protection through distinct

HMW CS at 40 µg. Four weeks after vaccination, mice were chal-

mechanisms.

lenged i.n. with a lethal dose of PR8 virus (5000 EID50). Two days
after the challenge, mice were killed for the examination of DLN
CD44+/CD4+ T‐cell production of IFN‐γ, IL‐4, and IL‐2 (Figure 8).

3.8 | HMW CS induces elevated IL‐2 producing
CD44+/CD4+ T cells in the DLN 2 days after
homologous challenge compared to LMW CS

CD44, a transmembrane protein that facilitates T‐cell migration and

T‐cell cytokine production in the DLN early after the viral challenge

groups in IFN‐γ and IL‐4 production by CD44+/CD4+ T cells in the

was also investigated to determine if T‐cell function in the DLN

DLN 2 days after homologous challenge (Figure 8a,b). However, mice

during the response to challenge was contributing to decreased

vaccinated with formulations that contained HMW CS‐induced

recruitment, expression was used as an indicator of activated and
antigen‐experienced CD4 T cells (Baaten et al., 2012).
No significant differences were observed between vaccination

(a)

(b)

(c)

F I G U R E 8 HMW CS as an adjuvant increases IL‐2 production by DLN CD4 T cells 2 days after challenge. Mice (n = 5) were vaccinated i.m.
with 1 µg H1N1 PR8 HA ± 40 µg CS as an adjuvant. As positive control mice were infected with low‐dose PR8 (500 EID50). Four weeks after
vaccination mice were challenged with 5000 EID50 H1N1 PR8 virus. Two days after the challenge, mice were killed, and DLN T‐cell cytokine
production was examined using flow cytometry. IFN‐γ (a), IL‐4 (b), and IL‐2 (c) production by CD44+/CD4+ T cells was examined. *p ≤ .05,
**p ≤ .01, ***p ≤ .001, ****p ≤ .0001 by one‐way ANOVA with Tukey's multiple comparisons test. ANOVA, analysis of variance; CS, chitosan; DLN,
draining lymph node; EID, egg infective dose; HA, hemagglutinin; HMW, high molecular weight; IFN‐γ, interferon‐γ; IL‐4, interleukin 4; i.m.,
intramuscularly; LMW, low molecular weight [Color figure can be viewed at wileyonlinelibrary.com]
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significantly higher frequencies of IL‐2+ CD44+/CD4+ T cells com-

These distinct innate immune responses in vitro were accompanied

pared to mice receiving LMW CS (Figure 8c). No significant differ-

by different effects in vivo based on CS MW. Although mice receiving

ences were observed between mice receiving HA alone and those

either LMW or HMW CS as an adjuvant during vaccination displayed

receiving either LMW or HMW CS (Figure 8c). Examination of DLN

decreased morbidity following homologous viral challenge as evi-

CD4 T‐cell cytokine production indicated that HMW CS results in

denced by lower weight losses, LMW and HMW CS adjuvantation

elevated IL‐2 production by CD44+/CD4+ T cells compared to LMW

resulted in distinct adaptive immune responses. LMW CS resulted in

CS adjuvantation, suggesting that HMW and LMW CS adjuvantation

significantly elevated antigen‐specific IgG antibody titers over un-

during vaccination induce distinct T‐cell responses the following

adjuvanted vaccines, while HMW CS did not. However, HMW CS

challenge. Therefore, the observed LMW and HMW CS mediated

adjuvantation resulted in significantly increased CD69+/CD103+

protection against weight loss after challenge may be mediated

CD4 and CD8 T cells in the lung and cytokine production by CD4

through different mechanisms.

T cells compared to mice receiving LMW CS. Observed immune
responses are summarized in Table 1.
Previously, in vitro, CS has been shown to induce and enhance

4
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cytokine production in a variety of immune cells including BMDCs,
bone marrow‐derived macrophages, and peritoneal macrophages

In this study, CS was investigated as a potential vaccine adjuvant,

(Bueter et al., 2011; Carroll et al., 2016; Da Silva et al., 2009; Mori

examining the effect of CS MW on innate APC activation in vitro and

et al., 2012). Correspondingly, increased Il6, Ifnb1, and Cxcl10 mRNA

adaptive immune responses in vivo. Innate immune APC activation

levels in BMDCs were observed here after 24 and 48 h treatment

was observed after CS treatment, evidenced by elevated cytokine/

with LMW (MW: 50–190 kDa) and HMW CS (MW: 310–375 kDa).

chemokine mRNA levels and activation markers. However, immune

We did observe a discrepancy in Il6 mRNA expression at 24 h, when

effects were dependent on the MW of the CS. LMW CS treatment

low‐dose (1 µg/ml) LMW and HMW CS‐induced higher levels of Il6

induced early cytokine mRNA responses in BMDCs, while HMW CS

expression than 10 µg/ml CS, yet at 48 h post LMW and HMW CS

treatment resulted in later cytokine mRNA responses and elevated

treatment, Il6 expression in the 10 µg/ml dose was quite high (6‐ and

expression of BMDC activation markers. The innate immune acti-

12‐fold, respectively). Without an extensive time course study, it is

vation resulting from LMW and HMW CS treatment appeared to be

difficult to conclude whether the lack of Il6 transcripts at 24 h in the

mediated by the IRF pathway, but not the NF‐κB pathway, and was

10 µg/ml dose represents a decrease in transcripts, or whether at

not associated with high levels of cell death after 24 h treatment.

that time point, mRNA transcription has yet to begin. Alternatively,

TABLE 1

Summary of immune responses observed after LMW and HMW CS treatment

Response (compared to negative control)

LMW CS

HMW CS

Positive control

24 h:

++++

+++

++ (MPLA)

48 h:

No significant effect

+++

+++ (MPLA)

BMDC surface activation markers

No significant increase

++

+++ (MPLA)

IRF pathway

++

++

++++ (MPLA)

IgG production

+

No significant increase

++++ (MPLA)

+

+

+++ (PR8)

Lung CD69 /CD103 CD4 and CD8 T cells

−

No significant effect

IL‐4 (lung CD4 T cells)

No significant effect

++

IL‐4 (lung CD8 T cells)

No significant effect

No significant effect

IFN‐γ (lung CD4 T cells)

No significant effect

No significant effect

IFN‐γ (lung CD8 T cells)

No significant effect

No significant effect

No significant effect

No significant effect

No significant effect

No significant effect

−

No significant effect

BMDC cytokine mRNA

Protection
+

+

+

+

IL‐4 (DLN CD44 /CD4 T cells)
+

+

IFN‐γ (DLN CD44 /CD4 T cells)
+

+

IL‐2 (DLN CD44 /CD4 T cells)

Note: + indicates increased responses compared to the negative control (no treatment/unadjuvanted vaccination). The number of +'s indicates the
magnitude of the response compared to the negative control.
Abbreviations: BMDC, bone marrow‐derived dendritic cell; CS, chitosan; DLN, draining lymph node; EID, egg infective dose; HA, hemagglutinin; HMW,
high molecular weight; IFN‐γ, interferon‐γ; IgG, immunoglobulin G; IL‐4, interleukin 4; IRF, interferon regulatory factor; LMW, low molecular weight;
mRNA, messenger RNA.
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low levels of Il6 mRNA expression in the 10 µg/ml condition may be

interactions with CD40‐ligand on T cells are involved in optimal in-

the result of negative feedback signals induced by dose treatment,

duction of T helper 1 (Th1) polarizing cytokine production and

although further investigation would be required to examine this

costimulatory molecule expression by DCs and subsequently IFN‐γ

effect. Carroll et al. (2016) also reported increased Il6 and Ifnb1

production by both CD8 and CD4 T cells (Caux et al., 1994; Cella

mRNA and protein expression after treating BMDCs with CS (MW:

et al., 1996; Fujii et al., 2004; Ma & Clark, 2009; Mackey et al., 1998;

150–400 kDa). This effect was dependent on a cyclic‐di‐GMP‐AMP

McLellan et al., 1996; Van Kooten & Banchereau, 1997).

synthase (cGAS) and stimulator of IFN genes (STING). While ele-

CD40:CD40‐Ligand interaction between DCs and CD8 T cells, re-

vated cytokine and chemokine mRNA after both LMW and HMW CS

spectively, are also important for cross‐priming of CD8 T cells

treatment was observed here, LMW and HMW CS treatment‐

(Bennett et al., 1998; Schoenberger et al., 1998). The work reported

induced differential responses at 24 and 48 h. The difference in cy-

here supports previous work that suggests CS treatment can in-

tokine mRNA level after LMW versus HMW CS treatment suggests a

crease BMDC surface activation marker expression in response to

disparity in the kinetics of the response to LMW CS and HMW CS,

CS treatment, although there are differences observed between this

indicating APC may have differing abilities to activate adaptive im-

report and previous reports by other groups, presumably due to

mune responses based on the MW of CS used. It has been hy-

differences in the properties of the CS used and the treatment

pothesized that CS adjuvant effects may be mediated through

duration. Additionally, CS MW appears to impact the resulting

interactions with the cellular membrane or currently undefined host

BMDC marker expression, with HMW CS inducing significantly

receptors (Moran et al., 2018). Because CS MW has been shown to

higher CD80, CD86, and MHC class II expression in BMDCs over

impact both CS protein interactions and phospholipid bilayer dis-

cells treated with LMW CS; this again supports that MW has the

ruption, these functions could be mediating the differences observed

potential to impact how APC function, and, therefore, how the APC

in the immune responses induced by LMW and HMW CS (Bekale

may activate the adaptive immune response during vaccination.

et al., 2015; Fang et al., 2001). Further studies should be conducted

Despite observing differences in cytokine/chemokine mRNA

to elucidate the mechanism through which CS activates immune

production kinetics and induction of BMDC activation markers be-

responses and how MW impacts this mechanism.

tween LMW and HMW CS treatment, both types of CS‐induced si-

In addition to cytokine and chemokine mRNA expression, BMDC

milar patterns and levels of IRF activation. In contrast, neither LMW

surface activation marker expression was also assessed. Significantly

nor HMW CS activated the NF‐κB pathway, despite increases in Il6

increased expression of CD80, CD86, and MHC class II on BMDCs

mRNA. Activation of the IRF pathway by CS treatment observed

treated with HMW CS were observed, consistent with BMDC acti-

here supports work done by other groups that have found that

vation. In contrast, this increase in BMDC surface activation markers

2–8 µg/ml CS (MW: 150–400 kDa) treatment of BMDCs induced

was not observed when cells were treated with LMW CS, again

cGAS and STING activation, upstream of the IRF pathway, indirectly

supporting that MW of the CS impacts BMDC activation in vitro.

as a result of mitochondrial DNA release (Cai et al., 2014; Carroll

Previous reports have also demonstrated that CS and CS‐coated

et al., 2016; Chen et al., 2016). In further support of indirect acti-

culture surfaces are able to induce expression of activation markers

vation of the IRF pathway, delayed IRF signaling in response to CS

in BMDCs (Carroll et al., 2016; Jia et al., 2014; Lin et al., 2014;

treatment was observed here and by Carroll et al. (2016) (CS: 2 µg,

Oliveira et al., 2012; Villiers et al., 2009). The mechanism through

MW: 150‐400 kDa) compared to the control MPLA, a known agonist

which CS induces the upregulation of CD86 and MHC class II is

of TLR4. Importantly, our results do not suggest that CS treatment is

unclear; however, previous reports have implicated multiple host

accompanied by high levels of cell death, which could result in the

cellular components including the IFN‐α:IFN‐β receptor, STING, and

release of DNA from the mitochondria. Taken together, the work

TLR4 (MW: 150–400 kDa (Carroll et al., 2016) or MW: unreported

reported here examining IRF activation after CS treatment supports

(Dang et al., 2011; Villiers et al., 2009)). In contrast to the results

the work done by others suggesting LMW and HMW CS may act by

reported here, Carroll et al. (2016) (24 h CS treatment, dose: 8 µg/ml,

activating cGAS/STING.

MW:

150–400 kDa

with

75%–90%

deacetylation)

and

Jia

The results reported here also support previous work sug-

et al. (2014) (48 h CS treatment, dose: 1 µg/ml, MW: unknown) re-

gesting that CS can successfully act as an adjuvant in an IAV

port modest, but significant increases in CD40 expression in BMDCs

vaccine model (Chang et al., 2010; Wang et al., 2012). Mice vac-

after CS treatment. Differences between those reports and the

cinated with formulations containing either LMW or HMW CS

CD40 expression reported here may be due to longer treatment

experienced significantly less weight loss after the homologous

durations compared to our study (48 vs. 24 h) and CS properties,

IAV challenge. Despite varied innate effects, LMW‐ and HMW‐

with our study examining LMW CS (50–190 kDa with 75%–85%

induced protection from weight loss did not significantly differ.

deacetylation) and HMW CS (310–375 kDa with greater than 75%

The observed decrease in weight loss after the homologous chal-

deacetylation) (Carroll et al., 2016; Jia et al., 2014). The lack of CD40

lenge is consistent with other reports of enhanced protection from

upregulation after LMW and HMW CS treatment may be responsible

weight loss in vivo after IAV infection in mice receiving CS ad-

for the lack of enhanced IFN‐γ responses seen after vaccination with

juvanted vaccination (Chang et al., 2010; Wang et al., 2012).

either variant of CS over unadjuvanted vaccines. Although CD40,

However, those studies used live attenuated (Wang et al., 2012) or

unlike CD80/86, is not required for activation of T cells, CD40

whole inactivated (Chang et al., 2010) vaccines and CS with
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Although we, like other groups (Carroll et al., 2016; Chang et al.,

tein was used, limiting the antigen quantity and available epitopes.

2010; Ghendon et al., 2008, 2009; Heffernan et al., 2011; Sui, Chen,

The use of a low antigen dose may allow for the differential effects

Wu, et al., 2010; Wang et al., 2012), report enhanced antibody re-

of LMW and HMW CS treatment to be observed when high levels

sponses in mice vaccinated with CS as an adjuvant compared to

of antigen are not available to mask modest MW effects. Our

those receiving antigen alone, weight loss trends observed in our

studies highlight that both LMW and HMW CS provide increased

report indicate that mice vaccinated with 1‐µg HA protein combined

protection with low antigen dose; however, this protection may be

with LMW or HMW CS are not afforded to sterilize immunity against

mediated by different mechanisms as distinct antibody response

homologous IAV challenge. As discussed above this result may be

magnitudes and T‐cell responses were observed here between

connected to the low dose of antigen used in our study resulting in

LMW and HMW CS.

antigen being the dose‐limiting factor. However, this weight loss

Accompanying the enhanced protection observed after i.m.

could also be indicative of cell‐mediated immunity, as opposed to

vaccination containing LMW and HMW CS, mice receiving LMW CS

immunity mediated by neutralizing antibodies. Significantly different

also displayed increased antigen‐specific IgG responses 4 weeks

CD69+/CD103+ CD4 and CD8 T‐cell populations were observed in

after vaccination compared to unadjuvanted vaccines. In addition, a

the lungs of LMW and HMW CS vaccinated mice 5 days after

trend toward elevated IgG1 after both LMW and HMW CS vacci-

homologous challenge. In addition, elevated IL‐4 production was

nation was observed compared to antigen alone. Previously reported

observed by CD4 T cells in the lung 5 days after challenge in mice

work has shown that both IgG1 and IgG2a subtypes contribute

vaccinated with HMW CS compared to mice receiving unadjuvanted

distinctly to protection against IAV (Huber et al., 2006). However,

vaccines. This elevated frequency of IL‐4 CD4 T cells was not ob-

expression of both subtypes, as reported here in mice previously

served in mice receiving LMW CS. In the DLN 2 days after the

infected with low‐dose PR8, provides superior protection (Huber

challenge, it was also observed that HMW CS vaccinated mice dis-

et al., 2006). IL‐4 is known to regulate and induce IgG1 isotype

played significantly higher frequencies of IL‐2 producing CD44+/

switching (Moon et al., 1989). Therefore, the trend of elevated IgG1

CD4+ T cells compared to mice receiving LMW CS. The predominant

expression after CS adjuvantation may be a result of the observed

Th2‐like IL‐4 and IL‐2 producing T‐cell response demonstrated in this

increase in IL‐4 production by CD4 T cells in CS, particularly HMW

study is opposite to what Carroll et al. (2016) observed in their

CS, vaccinated mice. In this study, the increased IL‐4 production by

report, in which the predominant response was more Th1‐like with

CD4 T cells, which correlates with elevated IgG1 in CS vaccinated

high levels of IFN‐γ expressing CD4 cells and IgG2c responses. This

mice, may contribute to enhanced protection observed in CS vacci-

difference may be due to differences in the properties of the CS

nated mice compared to mice administered unadjuvanted vaccines.

preparations as discussed previously, but also may represent a dif-

However, the majority of IL‐4 expressing CD4 cells were observed in

ference in the in vivo experimental conditions between the two re-

the lung, as opposed to the LN, suggesting IL‐4 upregulation may also

ports. Carroll et al. (2016) used 2 µg of antigen per mouse together

have a direct effect on the lung microenvironment. Typically, cyto-

with 100 µg of CS, which is a twofold higher antigen and adjuvant

kines such as IFN‐γ secreted by both CD4 and CD8 T cells are im-

dose than our report. In addition, Carrroll et al. (2016) injected an-

portant for IAV clearance during infection (Brown et al., 2004), but

tigen and adjuvant intraperitoneally, as well as used a prime/boost

IL‐4 may be important in blocking some proinflammatory responses

vaccination scheme with injections at Days 0 and 14. Our results are

in the lung as it has been shown to have a dual role in lung injury

after a single, low antigen dose (1 µg per mouse) vaccination scheme,

(Huaux et al., 2003). In addition, Bueter et al. (2011) reported that CS

in which we model an IAV vaccine delivered i.m. and test immunity in

activated the NLRP3 inflammasome, resulting in IL‐1β production.

the T‐cell compartment at mucosal sites after challenge. It has been

With the IL‐1R1 playing a role in the induction and sustainment of

shown that the level of antigenic stimulation can influence the de-

the CD4 Th2 (IL‐4 producing) subtype (Santarlasci et al., 2013), ac-

velopment of Th2 (IL‐4 producing) and Th1 (IFN‐γ producing) CD4

tivation of the inflammasome may be contributing to the IL‐4 pro-

effectors with moderate levels of antigen contributing to the dif-

duction reported here. Although early work suggested that the

ferentiation of IL‐4 secreting CD4 cells and high levels of antigen

presence of IL‐6, which was induced in BMDCs hereafter CS treat-

promoting more IFN‐γ secreting CD4 cells (Kaiko et al., 2008).

ment, increased IL‐4 production by CD4 T cells (Diehl et al., 2000;

Clearly, many factors contribute to vaccine‐induced responses after

Dienz & Rincon, 2009; Garbers et al., 2018; Rincón et al., 1997), more

antigen and CS administration, including the properties of CS, anti-

recent work has shown that IL‐6 in the presence of other polarizing

gen dose, vaccination site, and prime/boost schemes.

cytokines, such as transforming growth factor‐β/IL‐23 or tumor ne-

Together the analysis of the T‐cell populations and cytokine

crosis factor‐α, induces production of other CD4 T cell subset de-

production in LMW and HMW CS vaccinated mice suggests that the

fining cytokines, IL‐17 and IL‐22, respectively (Dienz & Rincon, 2009;

two MW variants of CS have distinct effects on T‐cell responses

Garbers et al., 2018; Snapper et al., 1988). Therefore, the entire

when acting as vaccine adjuvants. These distinct effects may be the

cytokine milieu is critical in defining CD4 T‐cell response, and further

result of differential APC activation following LMW and HMW CS

work is required to elucidate the effect of CS adjuvantation on CD4

adjuvantation, as was observed in vitro. Another possibility to ex-

T‐cell activation, and the subsequent impact on the immune response

plain these differences is the antigen depot effect that has been

including B‐cell responses.

attributed to some CS preparations (Markushin et al., 2018; Zaharoff
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et al., 2007). This depot effect is thought to enhance and sustain

Maurstad et al., 2007; Ravi Kumar, 2000; Shukla et al., 2013), which

vaccine‐induced immunity by providing a slow release of antigen at

should also be carefully studied in future studies to fully understand

the injection site, and was originally reported as a potential me-

how CS properties can affect its use as a vaccine adjuvant.

chanism of action of alum, a well‐known adjuvant used in human
vaccines (Marrack et al., 2009). However, there is still some con-
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